Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Randox Adiponectin Assay Gains CE Approval

Published: Thursday, June 05, 2014
Last Updated: Thursday, June 05, 2014
Bookmark and Share
The Company’s technology has brought a superior option for Adiponectin assessment to the clinical diagnostics market.

World-leading diagnostics firm Randox Laboratories has recently launched   a biochemistry Adiponectin assay. Testing adiponectin allows assessment of the risk of developing Type 2 diabetes and Cardiovascular Disease (CVD). In using Latex-Enhanced Immunoturbidimetric technology, Randox have brought a superior option for Adiponectin assessment to the clinical diagnostics market.

Adiponectin is a protein hormone produced and secreted exclusively by adipocytes. It regulates the metabolism of lipids and glucose, and influences the body's response to insulin. Adiponectin also has anti-inflammatory effects on the cells lining the walls of blood vessels. Low levels of Adiponectin therefore can be indicative of insulin resistance (leading to type 2 diabetes), and Cardiovascular Disease (CVD).  Low adiponectin levels have also been shown to correlate with increased likelihood of a woman developing gestational diabetes in pregnancy.

Randox also offers 2 levels of adiponectin controls as well as an adiponectin calibrator, delivering a complete testing package.

Speaking after the approval announcement, Randox Managing Director Dr Peter FitzGerald said,

“It is clear that in the 21st Century, increasing sedentary and deskbound lifestyles are driving chronic conditions such as diabetes and cardiovascular disease. 382 million people currently live with diabetes across the world and according to the International Diabetes Federation, this figure is predicted to rise by 55% by 2015. Adiponectin assesses an individual’s risk of developing diabetes, and allows resources and treatment to be focused on those patients most at risk. This highly targeted strategy should help to decrease the number of people becoming diabetic, while using resources most effectively.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Health Watchdog Calls For Changes To CKD Testing
Precision test detects minute deterioration in kidney function and identifies patients at early stages.
Tuesday, April 07, 2015
New €25 Blood Test A Breakthrough In The Diagnosis Of Bowel Cancer
New blood test will spot bowel cancer at earliest stage, removing the need for ‘unpleasant’ faecal screens.
Thursday, February 05, 2015
Randox Announce Plans for New Science Park
Plans include £161m investment and creation of 540 jobs.
Thursday, January 15, 2015
Diagnostics Leader Delivers New Fertility Service For UK
Randox launches new fertility service.
Thursday, November 27, 2014
Randox TxB Cardio Assay Gains CE Approval
Randox Laboratories has secured CE marking for their TxB Cardio Assay.
Thursday, October 09, 2014
FDA Clears Randox Immunoassay for US Labs
A multi-analyte control, the Acusera Immunoassay Premium Plus combines 52 analytes including tumour markers, hormones, therapeutic drugs and Vitamin D.
Wednesday, September 17, 2014
Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos